First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial.

Moreno, C; Greil, R; Demirkan, F; Tedeschi, A; Anz, B; Larratt, L; Simkovic, M; Novak, J; Strugov, V; Gill, D; Gribben, JG; Kwei, K; Dai, S; Hsu, E; Dean, JP; Flinn, IW.
Haematologica.2022 Sep 1;107(9):2108-2120. doi: 10.3324/haematol.2021.279012.
https://pubmed.ncbi.nlm.nih.gov/35021599/